Why premature babies' first IV nutrition is at risk, and what the FDA is doing
Sept. 4, 2026 — The FDA has temporarily eased compounding rules after children's hospitals warned they could lose access to starter IV nutrition, the premixed dextrose, protein and calcium given to newborns, especially premature ones, right after birth. The agency says the products' main source is leaving the market, and there is no FDA-approved version to fall back on; the standardized products had been made by two outsourcing facilities that are closing.
Until March 8, 2027, other outsourcing facilities and hospital pharmacies may make 20 listed formulas under relaxed rules, with short shelf lives of 30 hours at room temperature or nine days refrigerated. The FDA cautions that compounded drugs are not reviewed for safety, effectiveness or quality before use, and says it is working with industry and other suppliers to increase supply.
The deeper cause is familiar. A 2019 FDA task force found that drugs in shortage tend to be low-priced sterile injectables, that makers get little reward for investing in quality, and that prices rarely rise enough during a shortage to draw new production. It recommended rating manufacturers' quality and more sustainable purchasing contracts. The clinical nutrition society ASPEN has issued guidance to help hospitals make the products safely.
The wall: The two closing facilities are not named in the sources found; no hospital shortfall has been reported; plans beyond March 8, 2027, are not stated.
Tier: Confirmed
Sources
- FDA release, Sept. 4, 2026
- FDA guidance, Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates
- Federal Register notice, Sept. 9, 2026
- FDA, Drug Shortages: Root Causes and Potential Solutions (2019)
- ASPEN clinical considerations
This newsfeed was produced and brought to you by Temporal Data Dynamics Technology. For more information, visit temporaldatadynamics.com.